Akeso has now been advised to submit a sNDA to Chinese regulators for cadonilimab’s approval in gastric cancer by an ...
Jiangsu Hengrui Pharma has chalked up a first-in-class approval for retlirafusp alfa, a bifunctional drug that targets PD-L1 ...
Akeso, Inc. (9926.HK) announced the presentation of a real-world study at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO G I), comparing cadonilimab ...
Trastuzumab-based regimens were the primary treatment for older adults with advanced HER2-positive gastric cancer before immunotherapy became standard. The study highlights substantial economic ...
January 15, 2026) - Nanjing Leads Biolabs Co., Ltd. (HKE: 9887) ("Leads Biolabs" or the "Company") today announced that Opamtistomig (LBL-024), its core investigational PD-L1/4-1BB bispecific antibody ...
Solnerstotug showed a 14% response rate and 62% disease control in PD-L1 resistant tumors, surpassing typical expectations. Significant responses were observed in Merkel cell carcinoma and ...
PD-1 and PD-L1 inhibitors are types of immune checkpoint inhibitors, which are immunotherapy medications for treating cancer. Immunotherapy helps the immune system find and kill cancer cells. Some ...
FDA’s Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI’s Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients Provided by ...
AUSTIN, Texas, Nov. 18, 2025 /PRNewswire/ -- Genprex, Inc. (GNPX) ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback